gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · OCGNHealthcareBiotechnology

Ocugen, Inc. Common Stock (OCGN)

$0.8745+17.35%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.87▼ 38.85% in range
Nov 4, 2025Low $0.70 · High $2.48Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ocugen closed at $0.87 on Nov 4, up 17.35%, 64.7% below its 52-week closing high. Volume of 8.8M shares was 1.26× its 20-day average (above normal).

Split-adjusted performance: -15.9% over one month, -39.9% over six months, -43.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.49M, up 8.4% from a year earlier, with a net margin of -1671.8%.

Short interest was 107.2M shares at the Oct 15 settlement, up 5.0% from the prior report (33.1% of float, 15.8 days to cover).

Market cap$296.6M339.1M shares
Revenue · quarter$1.5M+8.4% YoY
Diluted EPS$-0.07—
P/E · TTM—
Net margin-1,671.8%Gross 100.0%
Dividend yieldNone
52-week range0.70 – 2.48−64.7% from high
Volume8.8M1.26× 20-day avg
Volatility · 60d78.3%Annualised
Short % of float33.1%15.8 days to cover
Net cash$15.9MCash $100.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +12.6%1M −15.9%3M −29.5%6M −39.9%YTD −35.2%1Y −43.2%3Y +142.9%5Y −90.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum36
Revenue growth49
Net margin25
Value (low P/E)—
Size53

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short107.2M+5.0% vs prior
Days to cover15.8Settled Oct 15
% of float33.1%
Short vol. 10d59.4%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
OCGNOcugen$0.8745+17.35%−39.9%+8.4%−1671.8%—$296.6M
IPSCCentury Therapeutics$1.67+9.87%−28.6%———$302.4MCompare
SABSSAB Biotherapeutics$3.18+1.92%−16.3%———$289.3MCompare
AGENAgenus$6.97+4.50%+79.2%+34.4%−1.7%3.4$314.8MCompare
SCTXScribe Therapeutics$16.78+3.58%————$317.7MCompare
KYTXKyverna Therapeutics$5.160.00%−45.5%———$319.1MCompare
XFORX4 Pharmaceuticals$3.24+2.21%−26.0%+346.3%−183.5%—$321.2MCompare
LXEOLexeo Therapeutics$3.23+3.86%−48.2%———$265.1MCompare
LCTXLineage Cell Therapeutics$1.03+1.98%−28.0%−61.3%138.6%—$260.5MCompare

News about Ocugen

All news →
Ocugen to Participate in Upcoming July Industry ConferencesGlobeNewswire Inc. · Jul 1, 2026▲ Positive

Quick answers

What does Ocugen do?
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform.
What is OCGN's market cap?
$296.55M, based on the Nov 4 close of $0.87.
Does Ocugen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of OCGN is sold short?
107.2M shares, 33.1% of float, as of Oct 15, 2026.
What sector is OCGN in?
Healthcare, in the Biotechnology industry.

About Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

HQ: Malvern, PA116 employeesListed Dec 3, 2014ocugen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology